Daniel O'Day

Gilead Sciences

Daniel O’Day is Chairman and CEO of Gilead Sciences. Like the thousands of other Gilead employees around the world, he is passionate about making the world a healthier, more equitable place for everyone. Daniel joined Gilead in 2019 and has led the company’s broader diversification into new cancer therapies and medicines for inflammatory diseases. The company has been a leader in virology for 30 years with a legacy that includes pioneering medicines for HIV, a cure for hepatitis C and, more recently, the first FDA-approved therapy for COVID-19. Daniel’s career also spans three decades with Hoffman La

HLTH does not sell or provide any personal data (including email, phone, address) to any third parties and we never will. Any communication that pretends to be HLTH or any third parties selling purported lists, discounted rooms, or any product/services are NOT AFFILIATED with HLTH and are to be considered FRAUD.

Upcoming Event Dates

2024 | ViVE: Feb 25-28; HLTH Europe: Jun 17-20; HLTH US: Oct 20-23

2025 | ViVE: Feb 16-19; HLTH US: Oct 19-22

2026 | HLTH US: Nov 15-18

2027 | HLTH US: Oct 17-20

© 2024 HLTH, INC. All Rights Reserved